Eli Lilly's Retatrutide Cuts Blood Sugar & Weight in Trial

Eli Lilly's triple-G drug retatrutide showed significant HbA1C and weight reductions in type 2 diabetes patients at 40 weeks in a 2026 late-stage trial.